West Yorkshire ICB Approves Community Palpitation Pathway Using Zenicor One
The care pathway enables patient assessment in primary care, avoiding unnecessary secondary care referrals. Zenicor One, an easy-to-use thumb ECG, supports timely, accurate diagnosis of intermittent arrhythmias and reassures patients with benign symptoms—crucial to the pathway’s effectiveness.
Palpitations Plus began as a pilot in Wakefield, a district serving around 350,000 residents, and has now secured permanent ICB funding after demonstrating cost savings, improved patient outcomes, reduced wait times, and positive feedback from both GPs and patients.
“We are pleased to have secured long-awaited support from the ICB, marking a major milestone for patients and GPs in Wakefield. This funding strengthens our community-based palpitation pathway, enabling more timely, accessible care and reducing reliance on hospital investigations. With Zenicor One as a practical and effective tool for detecting intermittent arrhythmias, GPs can manage patients more confidently in primary care. We believe this model has strong potential for wider adoption, offering clear system-wide benefits by improving outcomes and easing the burden on secondary care,” says Dr. Murad Khan, GP and Cardiologist, Clinical Lead at Health Care First Partnership and founder of the Palpitations Plus service
“The reimbursement of Zenicor One as part of a community-based care pathway further validates its clinical value in early detection of arrhythmias. It enables broader access to diagnostics, supports long-term use, and helps reduce pressure on secondary care. We see this as a key milestone in our UK expansion and hope other ICBs will adopt similar pathways across England,” says Kaisa Rahkala, General Manager of Zenicor Ltd.
About Zenicor
Founded in 2003, Zenicor Medical Systems is a leading provider of ECG-based solutions for arrhythmia diagnostics and stroke prevention. In collaboration with healthcare providers, Zenicor develops integrated care pathways that enhance patient outcomes and optimise resource use.
For more information, visit: www.zenicor.com
For more information, please contact: Mats Palerius, CEO, Zenicor Medical Systems AB
+46 8 442 68 60 mats.palerius@zenicor.se
High-resolution images for download: https://zenicor.com/press-material/
This is an English translation of the original Swedish press release published on June 25, 2025.
